Jing Lin

7PUBLICATIONS
17CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 05, 2026
Efficacy and Safety of DNV3 (a Lymphocyte-activation Gene 3-blocking Antibody) Combined With Toripalimab and Chemotherapy in Advanced Melanoma: An Open-label, Single-arm Clinical Trial.

Jing Lin, Lizhu Chen, Ling Chen

|Jan 21, 2026
Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system.

Huang Xia, Lei Shi, Shuimei Luo

|May 03, 2025
Differences of clinical features, prognosis and genetic mutations in Chinese patients with malignant melanoma and additional primary tumours.

Jing Lin, Zhongqiao Lin, Yanping Chen

|Jan 06, 2025
Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3-year survival update and multi-omics analysis.

Jie Dai, Tianxiao Xu, Lifeng Li

|Nov 30, 2023
Clinicopathologic features and prognosis of 71 patients with gastric cancer and disseminated intravascular coagulation.

Ling Chen, Jing Lin, Yu Chen

|Aug 31, 2022
Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study.

Lili Mao, Meiyu Fang, Yu Chen

Pageof 2

Frequent Collaborators

3 joint publications

Yu Chen

2 joint publications

Ling Chen

2 joint publications

Lu Si

1 joint publications

Lili Mao